Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.

Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.

FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.

Celltrion presents encouraging phase III data for CT-P47, a biosimilar of RoActemra® (tocilizumab), in RA patients at EULAR 2024.

ELREXFIO™ Demonstrates Over Two-Year Median Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma.

Vertex Showcases Promising Long-Term Results for CASGEVY™ (exagamglogene autotemcel) at the 2024 EHA Congress.

Zura Bio Limited has recently unveiled positive results from a Phase 1 trial of its leading drug candidate, tibulizumab (ZB-106), aimed at treating Sjogren’s syndrome.

Genentech's Phase III STARGLO Trial Shows Columvi Significantly Prolongs Survival in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

KSQ Therapeutics Begins Clinical Trials with Initial Patient Dosed for CRISPR/Cas9 Modified eTIL® Therapy KSQ-001EX.

Avidity Reveals Remarkable Phase 1/2 FORTITUDE™ Trial Results for AOC 1020 Showing Over 50% Decrease in DUX4 Genes and Functional Improvement Trends in Facioscapulohumeral Muscular Dystrophy Patients.

Zumutor Biologics Inc. has recently disclosed that the initial patient has been treated in its Phase 1 clinical trial with ZM008.

Nektar Therapeutics Unveils Initial Preclinical Findings on NKTR-0165, a TNFR2 Agonist Antibody for Inflammatory Disease Therapy, at EULAR 2024.